Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

14.13 -4.07

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

14.18

Belangrijke statistieken
By Trading Economics
Inkomsten	-4.3M -18M
EPS	-0.19
Werknemers	37
EBITDA	-5.3M -17M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+108.33% upside

Dividenden
By Acuity
Volgende Winsten	3 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	61M 1.2B
Vorige openingsprijs	18.2
Vorige sluitingsprijs	14.13

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 aug 2026, 23:51 UTC

"Bitcoin and Ethereum Rise Amid Market Uncertainty; Barclays Warns of Commodity Shock, Fed Signals Possible Rate Hikes, and Canada's GDP Growth Falls Short of Expectations."

29 aug 2026, 23:51 UTC

Bitcoin and Ethereum rise amid economic uncertainties, while Barclays warns of a commodity shock and Fed Chair hints at potential interest rate hikes.

29 aug 2026, 23:51 UTC

Cryptocurrency gains amid economic uncertainty; Barclays warns of commodity shock from El Niño, while Fed signals potential rate hikes and Canada faces trade tensions.

29 aug 2026, 23:51 UTC

Cryptocurrency gains amid economic uncertainty, while Barclays warns of commodity shocks and Fed signals potential rate hikes, impacting U.S. stock markets and Canadian trade tensions.

29 aug 2026, 23:41 UTC

U.S. Import Data Release on September 3, 2026 Expected to Reflect Impact of Tariff Changes Amid Escalating Trade Tensions with Canada.

29 aug 2026, 23:41 UTC

U.S. Trade Deficit Expected to Widen to $86.4 Billion Amid Ongoing Tariff Tensions with Canada

29 aug 2026, 23:41 UTC

Mexican Business Confidence Remains Low Ahead of September Survey, Anticipating Continued Economic Challenges

29 aug 2026, 23:41 UTC

U.S. July 2026 export data release on September 3 expected to reflect ongoing trade challenges amid U.S.-Canada tariff tensions, raising market volatility concerns.

29 aug 2026, 23:41 UTC

Canada's Balance of Trade Expected to Show C$3.2 Billion Surplus Amid Rising U.S.-Canada Tariff Tensions

29 aug 2026, 23:31 UTC

Brazil's Q2 2026 GDP Growth Rate Release on September 1st Sparks Cautious Optimism Amid Economic Challenges and Global Trade Tensions.

29 aug 2026, 23:31 UTC

South Africa's Balance of Trade report on August 31 expected to reveal if trade surplus continues amid concerns over El Niño impacts and global commodity markets.

29 aug 2026, 23:11 UTC

ADP Employment Change report on September 2 forecasts a modest increase of 47,000 jobs amid cautious labor market sentiment and potential downward revisions in nonfarm payrolls.

29 aug 2026, 23:11 UTC

Mexican Consumer Confidence Index Set for Release on September 3, Amid Global Economic Uncertainty and Mixed Sentiments.

29 aug 2026, 23:01 UTC

Macro News

DAX 30 Index declines in after-market hours, pressured by hawkish Fed remarks and geopolitical tensions. The index remains near its one-month low.

29 aug 2026, 22:52 UTC

Japan's Household Spending Data Release Sparks Caution Amid Rising Inflation Concerns and Weak Investor Confidence

29 aug 2026, 22:52 UTC

Japan's Household Spending Expected to Decline by -1.6% YoY Amid Inflation Concerns and Weak Consumer Sentiment

29 aug 2026, 22:52 UTC

Brazil's Q2 GDP Growth Rate Release on September 1, 2026, Sparks Cautious Market Anticipation Amid Global Economic Uncertainties.

29 aug 2026, 22:51 UTC

Correlated Moves

Barclays reports a potential commodity shock from adverse weather and underinvestment. In after-market trading, Silver Ounce vs Euro is roughly flat near its one-month range.

29 aug 2026, 22:41 UTC

Upcoming MBA Mortgage Rate Release Sparks Cautious Investor Sentiment Amid Inflation and Fed Hike Expectations

29 aug 2026, 22:11 UTC

Germany's Inflation Rate Expected to Rise to 2.9% in August Amid Fed Concerns Over Elevated Prices

29 aug 2026, 22:11 UTC

Germany's Inflation Rate Release on August 31 Sparks Investor Caution Amid Persistent Price Pressures and Potential Monetary Policy Tightening.

29 aug 2026, 22:11 UTC

Japan's Q2 2026 Capital Spending YoY data set for release, with a modest growth forecast of 0.2% amid cautious investor sentiment and rising inflation concerns.

29 aug 2026, 21:51 UTC

Japan's Industrial Production Expected to Contract 0.006% in July Amid Mixed Economic Sentiment and Rising Inflation Concerns

29 aug 2026, 21:51 UTC

Japan's Retail Sales YoY data for July 2026 expected to rise by 0.3% amid mixed economic signals and wavering investor confidence ahead of the release on August 30, 2026.

29 aug 2026, 21:41 UTC

South Africa's Business Confidence Index set for release amid cautious market sentiment following significant declines and ongoing geopolitical uncertainties.

29 aug 2026, 21:41 UTC

Australia's Ai Group Industry Index set for release on September 1, 2026, amid cautious expectations of continued industrial contraction due to high costs and subdued demand.

29 aug 2026, 21:41 UTC

South Korea's Upcoming Inflation Rate Release on September 1, 2026, Expected to Impact Economic Outlook Amid Mixed Market Sentiment and Global Price Pressures.

29 aug 2026, 21:31 UTC

API Crude Oil Stock Change Data Release on September 1, 2026, Expected to Impact U.S. Market Amid Rising Inventories and Geopolitical Tensions

29 aug 2026, 20:41 UTC

India's Q2 2026 GDP Growth Rate Forecast at 7.1% Amid Cautious Optimism and Global Economic Pressures

29 aug 2026, 20:31 UTC

Euro Area Retail Sales Expected to Rise 0.3% in July Amid Mixed Economic Signals and Caution from Spain's Decline

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

108.33% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.5 USD 108.33%

Hoogste 33 USD

Laagste 27 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.